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Summary
Background: Erythema nodosum leprosum (ENL) is a painful, multisystem
immune mediated complication of borderline lepromatous and lepromatous leprosy.
The management of ENL may be complex and often requires prolonged
administration of immunomodulatory drugs including thalidomide.
Thalidomide is very effective in controlling ENL although its mode of action in ENL
is not well understood. Teratogenicity and cost limit its use in many settings. In
addition to teratogenicity, thalidomide is reported to have a wide range of adverse
drug reactions including neurotoxicity. The non-teratogenic adverse drug reactions
associated with thalidomide in patients with ENL have not been systematically
reviewed. We have reviewed the literature to determine the adverse drug reactions
attributable to thalidomide in the management of ENL.
Methods: Several databases were searched using the relevant terms. Articles found
were reviewed according to the PRISMA protocol. The eligibility of the articles was
agreed by both authors.
Results: A total of 45 papers from 1965–2017 were systematically reviewed. Eight
of these were randomised control trials (RCTs), nine non-randomised clinical trials,
three prospective studies, five retrospective studies and 20 case reports.
The papers included 1,673 participants with 1,017 (61%) receiving thalidomide. The
most frequent adverse drug reaction encountered was drowsiness, in 13·5%. The
frequency of constipation was 13·4% and dizziness 6·8%. Other events were reported
in less than 5% of participants. Severe adverse reactions such as pulmonary embolism
and peripheral neuropathy were uncommon. Only one fatality was reported, the cause
of which was uncertain. Thalidomide had to be withdrawn in 67% of individual case
reports but only in four patients in the clinical studies.
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Leone (e-mail: m_mahmoud85@yahoo.com)
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Conclusions: Thalidomide is a potentially safe and effective drug for use in the
management of ENL. There is limited information about thalidomide-induced
neurotoxicity in patients with ENL and this needs further study.
Thalidomide is an effective alternative to long-term corticosteroids which have
significant adverse effects. It must be administered in a closely supervised way and
requires adherence to robust guidelines by prescribers.
Introduction
Erythema nodosum leprosum (ENL) or leprosy Type 2 reaction is an immune mediated
inflammatory reaction which occurs in approximately 5–10% of people with borderline
lepromatous (BL) leprosy and in up to 50% of individuals with lepromatous leprosy (LL).1
The odds of LL patients developing ENL are 8·4 times greater than of individuals with BL
leprosy. The odds for BL patients with bacteria index $4 are 5·2 times greater than BL
patients with bacterial index ,4.1
ENL is a very painful condition.2 It is characterised by the occurrence of crops of painful
new cutaneous and subcutaneous nodules, which are often associated with fever. ENL is a
multisystem disorder and may also affect the eyes, bones, kidneys, testes, joints, lymph nodes
and peripheral nerves.2
The pathophysiology of ENL is not well understood. A large systematic review of the
immunological studies of ENL found little evidence for immune complexes which are often
cited as causing ENL. Pro-inflammatory cytokines such as tumour necrosis factor alpha
(TNF-a), IFN-g and Interleukins 1 and 6 (IL-1, IL-6) may be increased in ENL patients but
their role is unclear. The infiltration of high numbers of neutrophils and polymorphonuclear
cells (PMN) into the lesions and throughout the dermis and subcutis is characteristic of
ENL.3,4 The recruitment of large numbers of neutrophils leads to their adhesion to endothelial
cells and TNF-a production.
ENL is usually chronic and is often treated with high dose oral corticosteroids. The use of
corticosteroids is associated with significant morbidity and mortality.5
Tachyphylaxis to corticosteroids occurs in ENL patients and necessitates increasing doses
to control symptoms. Other agents such as thalidomide, clofazimine, minocycline, ciclosporin
and methotrexate are used as alternatives or for “steroid-sparing”.6
Thalidomide (a-phthalimido glutarimide) is a glutamic acid analogue first developed in
1954 in West Germany by the Chemie Gru¨nenthal drug company. It was sold as an anti-
emetic and a sedative.7 It was widely used in Europe, Australia and Canada for treating
anxiety, insomnia, gastritis, and for the management of morning sickness in pregnant women,
before being found to be teratogenic.
Teratogenicity occurs between days 20–36 post-conception.6 Phocomelia is the most
commonly recognised feature of thalidomide embryopathy and is characterised by reduced or
missing long bones, with the distal elements of the limb spared. Other structures affected
include the eyes, external ear, the spine, palate, heart, kidneys, gastrointestinal tract and
genitals. Thalidomide suppresses the insulin-growth-factor 1 (IGF-1) and fibroblast growth
factor (FGF), which together stimulate limb initiation in utero.8,9 A more recent study in 2013
identified cerebron (CRBN) as the primary target of thalidomide and its analogues, leading to
teratogenicity.10
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Thalidomide is used in a variety of dermatological, oncological and inflammatory
conditions such as Behcet’s disease, metastatic prostate cancer, lupus erythematosus, graft-
vs-host disease, pyoderma gangrenosum, and sarcoidosis. Thalidomide and its analogues are
used in the treatment of myeloma. In myeloma they exert their effect by binding to the CRBN
complex promoting substrate degradation necessary for the management of myeloma and
other B-cell malignancies.10
The anti-ENL effect of thalidomide was discovered serendipitously by Sheskin in 1964.
He reported dramatic clinical improvement of individuals with ENL who were given
thalidomide for sedation.11
A Cochrane review published in 2006 showed some evidence of benefit of thalidomide
in the management of ENL.12 More recently a prospective longitudinal study reported
thalidomide to be superior to prednisolone in managing first episodes of ENL.13 A
randomised trial also reported a more rapid response of ENL to thalidomide than
prednisolone, lower recurrence rates and longer remission periods.14
In a retrospective study of patients with ENL treated with thalidomide at the Hospital
for Tropical Diseases, London, the doses used ranged from 12·5 mg–500 mg/day with a
maximum effective median dose of 400 mg/day.15
A major concern about the use of thalidomide is its neurotoxicity and this is particularly
the case in individuals with a pre-existing peripheral nerve disorders such as leprosy.
Thalidomide induced peripheral neuropathy, diagnosed using nerve conduction studies, is
frequently seen during the first year of treatment in dermatological conditions and has been
reported to affect up to 20% of individuals.16 It occurs as a painful paraesthesia, numbness, or
weakness, affecting the feet and hands in a glove-and-stocking like distribution.6 Nerve
function impairment associated with ENL does not appear to respond to thalidomide and is
usually managed with oral corticosteroids.6 There are no tests which differentiate between
thalidomide-induced neuropathy and nerve function impairment (NFI) due to leprosy.17
Thromboembolism is associated with thalidomide monotherapy in 3% of myeloma
patients18 but can increase to 14% when used in combination with corticosteroids.6
Other common adverse drug reactions (ADRs) listed in the summary of product
characteristics for thalidomide include drowsiness or somnolence, dizziness, neutropenia and
increased HIV viral load. Rarer ADRs of the drug include constipation, cardiac disturbances,
peripheral oedema, rash, raised liver enzymes and amenorrhea. These unwanted effects do
not always warrant the withdrawal of the drug and may be managed effectively during
therapy.19
There are large systematic studies of the ADRs of thalidomide in patients with
myeloma29,16,18,20 but there are no such studies in individuals with ENL. We wished to
conduct a systematic review of the ADRs associated with thalidomide therapy in ENL to
determine their frequency and to inform clinical practice.
Methods
The World Health Organization defines an adverse drug reaction (ADR) as “a response to a
drug which is noxious and unintended, and which occurs at doses normally used in man for
the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological
function.”21
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All randomised control trials (RCTs), and cohort studies of thalidomide in patients with
ENL and case reports of ENL managed using thalidomide after 1965 were included in this
systematic review. Articles reporting adverse drug reactions with thalidomide in ENL were
eligible for inclusion. The eligibility of the articles was agreed upon by the authors. Reference
bibliographies from all reviewed publications were also examined to identify further relevant
studies. There were no restrictions made based on the language in which the studies were
reported. Reports of teratogenicity of thalidomide were not included in this study.
The following databases were searched up until the 13th August 2017 using the search
strategy in Appendix 1: CINHAL plus, Cochrane, EMBASE, Global health, LILACS and
PUBMED. Similar articles of relevant searches were also reviewed.
Google scholar database was searched using a combination of “leprosy or lepromatous”,
“leprosy reactions or type 2 reactions or ENL” and “adverse reactions of thalidomide”. The
first 100 relevant items from this search were selected for review.
The contents of issues of the Indian Journal of Leprosy (http://www.ijl.org.in/index.html),
International Journal of Leprosy and Other Mycobacterial (http://www.leprosy-ila.org/
leprosyjournal/gn1/default.php?ed¼MTY1), and Leprosy Review (https://www.lepra.org.
uk/leprosy-review-index) hosted on the journals’ websites were searched manually to
identify additional articles.
CRITICAL APPRAISAL
The quality of the included studies and reports was assessed based on: appropriate
randomisation method; mode of allocation concealment; method of blinding; number of
participants lost to follow-up; collection of adverse reaction data properly described; bias
adequately minimised in recruitment, similar comparison groups or differences accounted
for; appropriate sampling and measurement. Each criterion grouped as applicable to the type
of study. Criterion were labelled Yes for adequate, No for inadequate, and U for unclear. See
Appendix 2.
Results
A total of 808 papers were collected from all searches and from references. After removal of
duplicates, 505 papers were excluded by screening of title and abstract, with 244 screened via
full text review (Figure 1).
45 papers were included in this review of which, eight were randomised control trials
(RCTs), nine non-randomised clinical trials, three prospective and five retrospective studies,
20 were case reports.
ANALYSIS OF 25 CLINICAL STUDIES
25 clinical trials were assessed during this study. 14 studies were published between 1965–
1990, and 11 between 2005–2016. A total of 1,671 participants were recruited with 1,015
(61%) of these cases reportedly treated with thalidomide. The number of cases in the
thalidomide group was unclear in one study and therefore not included in this percentage.22
Studies with un-quantified adverse effects will not be included in the following quantitative
analysis and will be discussed separately.
A Systematic Review of Adverse Drug Reactions associated with Thalidomide 145
RANDOMISED CONTROLLED TRIALS
Eight of the 45 studies reviewed (18%) were randomised controlled trials, published between
1965 and 2009 (Table 1). The adverse drug reactions from thalidomide could not be
quantified in one RCT and therefore it was not included in this analysis.23
In the seven studies where adverse reactions could be quantified, 268 participants were
enrolled with 196 (73%) receiving thalidomide therapy. The male to female ratio was 7:1.
Five of these studies were reported to be double-blinded,24 – 28 Kaur’s trial was not blinded
(14) and the allocation concealment technique was unclear in one study.29
The daily dose of thalidomide ranged from 50 mg to 400 mg. Treatment with thalidomide
varied between 7 days and 1 year. Four trials documented concomitant corticosteroid use in
all or some of the patients.25,26,28,29 Other studies either failed to mention the use of oral
corticosteroids or prohibited its use during the trial period. In a double-blind, double-dummy,
dose comparison RCT done by Villahermosa in 2005, patients who had taken corticosteroids
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Figure 1. PRISMA flow diagram.
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less than two weeks prior to the study were excluded.27 MDT for leprosy had been initiated in
majority of the trials done after 1982 and was continued after commencement of thalidomide.
Neurological ADRs reported in the RCTs
The studies reported rates of drowsiness/somnolence/sleepiness between 13 and 77%.
Overall, 58 (29·6%) of 196 patients treated with thalidomide had drowsiness. Dizziness
(including “giddiness” and “vertigo”) was experienced by 1–28% of participants, with an
overall of 28 (14·3%) of the 196 participants reporting this symptom. The proportion of
headaches reported in the individual studies ranged from 2–26%. 15 (7·7%) patients reported
headaches. There were three reports of “paraesthesia” and a case of unspecified “numbness”
documented.24 Kaur encountered two cases complaining of “inability to concentrate” during
therapy.14 One case of tremor was documented in an RCT done in 2005.27
Vascular ADRs
Peripheral oedema was reported in a total of nine (4·6%) of the 196 individuals on
thalidomide treatment, with proportions between 11–38% per trial. A case of
leukocytoclastic vasculitis occurred ten days into therapy and thalidomide was stopped.14
Gastrointestinal ADRs
Chronic or intermittent constipation was documented in 23 (11·7%) of the total 196 patients
and either resolved spontaneously or was managed symptomatically with laxatives. The
prevalence of constipation ranged from 1–69% in the studies. 19 (9·7%) patients were
reported to have experienced oral and nasal mucosal dryness in two studies. Other
gastrointestinal symptoms reported include six cases of increased appetite in one study, one
case of vomiting and an account of ravenous appetite for six months. The only female patient
enrolled in an RCT in 1969 developed intestinal obstruction of uncertain cause after nine
weeks of thalidomide and was withdrawn from the study.25 A patient with amoebic dysentery
within two weeks of starting therapy also warranted withdrawal of the drug.14
Cutaneous ADRs
Of the 196 patients on thalidomide during the trial period, 22 (11·2%) had a cutaneous
problem. 13 patients developed a “rash”, three had dermatitis, three had urticaria and three
were found to have vesiculobullous eruptions. The frequency of skin ADRs was highly
variable. Some studies documented only one case of skin lesions whilst in other studies skin
lesions occurred in 8–47% of participants. 12 (6·1%) other patients complained of itching or
pruritus without skin lesions. There were five cases of erythema of the face and chest in a
single study, and one case of “perifollicular skin thickening”.
Genitourinary ADRs
Three patients complained of erectile dysfunction after 2 months of thalidomide therapy,
whilst one participant reported to have not been able to have an erection for 7 months after
commencement of the drug.29
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NON-RANDOMISED CLINICAL TRIALS
Three of these nine clinical trials will be analysed with the studies with un-quantifiable
adverse reactions of thalidomide. The rest of the trials included a total of 248 participants, all
of which were on treatment with thalidomide in doses of 50 mg–400 mg daily (Table 2). The
male to female ratio was 25:1.30 The exposure to thalidomide was between 12 and 738
days.30,31 The administration of oral corticosteroids to all or some groups of participants was
documented in all but one trial.32
Neurological ADRs
The adverse drug reactions associated with thalidomide, drowsiness was reported by 25
(10·1%) of the 248 patients on therapy. One study reported only one case of drowsiness whilst
in another it affected all the participants.30,32 A total of ten reports of giddiness (11%) were
documented in one trial.33
Vascular ADRs
Pedal oedema was found in a combined total of 23 cases (9·3%) from the 248 patients on
thalidomide therapy.
Gastrointestinal ADRs
Constipation was the most frequently reported amongst the 248 patients on thalidomide. 24
patients (9·7%) complained of sustained or occasional constipation during therapy. All but
two trials listed constipation as an ADR of thalidomide. Seven participants (2·8%), in one
study, reported experiencing symptoms of “gastrointestinal upset”. There was one case each
of diarrhoea, oral mucosal dryness and flushing, and two cases of nausea. Two cases of
abdominal pain warranted the reduction of the dose of thalidomide.34
Nine reports of ADRs were labelled “miscellaneous” in a trial done by Parikh in 1986.31
PROSPECTIVE STUDIES
Three prospective studies were included in this review. The male to female ratio more than
20:1. 87 out of a total of 203 participants (42·9%) in these studies were treated with
thalidomide. Patients were started on thalidomide at doses between 100–400 mg daily
(Table 3). The duration of therapy but spanned four months to less than three years in others was
unclear in one study.36
Neurological ADRs
The most common adverse reaction mentioned was drowsiness/somnolence in 24 (27·6 %) of
203 cases. It was documented in 31% of individuals in one trial and in 95% of individuals in
another. Six participants (3%), reported headaches, four patients complained of paraesthesia
and dysesthesia (2%) and four patients encountered dizziness (2%) whilst on the drug.
Guillain-Barre syndrome was diagnosed in one patient after three weeks of thalidomide
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therapy.37 Symptoms of Guillain-Barre resolved completely after three months of withdrawal
of thalidomide and did not recur on re-introduction of the drug for over a year.37
Vascular ADRs
There was one report of deep venous thromboembolism (DVT) in a patient receiving
thalidomide and prednisolone, in a prospective longitudinal study.13 Thalidomide therapy
was discontinued after the occurrence of DVT.
Gastrointestinal ADRs
Constipation was documented in five of the 203 patients on treatment (2·5%), occurring in
10% of cases in one trial and in 19% of cases in another, whilst four patients experienced
gastric fullness (2%). There was only one case of nausea documented in these studies.36
RETROSPECTIVE STUDIES
291 participants were reported in these three retrospectives studies. The male to female ratio
was 7:1. The number of participants treated with thalidomide was 287 (98·6%). The lowest
dose administered was 12·5 mg daily15 (Table 4).
In De Las Aguas’ study, the participants had stopped taking oral corticosteroids before
starting thalidomide, but oral corticosteroids had to be restarted in a few patients because of
“rebound” reactions.38
Neurological ADRs
6 and 15% of patients in two studies had documented drowsiness/sedation/sleepiness. 16
(61%) of patients had tiredness in one study.39 Reported rates of dizziness of 10% and 15% in
two trials. There was one report of peripheral neuropathy diagnosed following thalidomide
therapy.40
Gastrointestinal ADRs
Constipation was the most frequently reported gastrointestinal adverse reaction associated
with thalidomide therapy. The prevalence in the three studies was 3%, 15% and 50%. Two
women in De Las Aguas’ study experienced abdominal “tympanism”.38 Withdrawal of
therapy was not necessary for these conditions.
STUDIES IN WHICH THE FREQUENCY OF THALIDOMIDE ASSOCIATED ADVERSE
DRUG REACTIONS WERE NOT QUANTIFIED
ADRs attributable to thalidomide were mentioned in six studies but the numbers of patients
experiencing these effects was not reported or was unclear.23,41 – 45 The studies consisted of
661 patients with more than 197 on thalidomide therapy (29·8%). These groups comprised
patients with a history of long-term usage of oral corticosteroids, patients who failed to
respond to oral corticosteroids or patients with corticosteroid-dependency.33,41,45 Convit did
his trial amongst patients with history of corticosteroid treatment and without, but none was
M. Mahmoud and S.L. Walker152
T
a
b
le
3
.
S
u
m
m
ar
y
o
f
P
ro
sp
ec
ti
v
e
S
tu
d
ie
s
A
u
th
o
r/
Y
ea
r
o
f
p
u
b
li
ca
ti
o
n
T
y
p
e
o
f
S
tu
d
y
N
u
m
b
er
o
f
p
ar
ti
ci
p
an
ts
P
at
ie
n
ts
w
h
o
re
ce
iv
ed
th
al
id
o
m
id
e
D
ai
ly
d
o
se
o
f
T
h
al
id
o
m
id
e
D
u
ra
ti
o
n
o
f
th
er
ap
y
C
o
-i
n
te
rv
en
ti
o
n
s
S
id
e
ef
fe
ct
s
at
tr
ib
u
ta
b
le
to
th
al
id
o
m
id
e
K
ar
&
G
u
p
ta
2
0
1
6
(1
3
)
P
ro
sp
ec
ti
v
e
st
u
d
y
N
¼
8
0
N
¼
4
0
A
ll
m
al
e
4
0
0
m
g
ta
p
er
ed
to
5
0
m
g
2
0
w
ee
k
s
M
D
T
P
re
d
n
is
o
lo
n
e
C
lo
fa
zi
m
in
e
D
ro
w
si
n
es
s
(3
1
%
),
C
o
n
st
ip
at
io
n
(1
9
%
),
D
V
T
(1
ca
se
)
V
al
en
te
&
V
ie
ir
a
2
0
1
0
(3
6
)
P
ro
sp
ec
ti
v
e
st
u
d
y
N
¼
2
0
N
¼
2
0
1
0
0
–
2
0
0
m
g
U
n
cl
ea
r
P
re
d
n
is
o
lo
n
e
S
o
m
n
o
le
n
ce
(9
5
%
),
1
6
M
;
4
F
M
B
-M
D
T
H
ea
d
ac
h
e
(3
0
%
)
G
as
tr
ic
fu
ll
n
es
s
(2
0
%
),
D
iz
zi
n
es
s
(2
0
%
),
P
ar
ae
st
h
es
ia
an
d
d
y
se
st
h
es
ia
(1
5
%
),
C
o
n
st
ip
at
io
n
(1
0
%
),
N
au
se
a
(1
ca
se
),
M
ag
o
ra
et
a
l.
1
9
7
0
(3
7
)
P
ro
sp
ec
ti
v
e
st
u
d
y
N
¼
1
0
3
6
1
M
;
4
2
F
N
¼
2
7
3
0
0
–
5
0
0
m
g
ta
p
er
ed
to
5
0
–
1
0
0
m
g
.
4
m
o
n
th
s
to
.
3
y
ea
rs
S
u
lf
o
n
es
P
re
d
n
is
o
lo
n
e
G
u
il
la
in
-B
ar
re
sy
n
d
ro
m
e
(1
ca
se
)
A Systematic Review of Adverse Drug Reactions associated with Thalidomide 153
T
a
b
le
4
.
S
u
m
m
ar
y
o
f
R
et
ro
sp
ec
ti
v
e
S
tu
d
ie
s
A
u
th
o
r/
Y
ea
r
o
f
p
u
b
li
ca
ti
o
n
T
y
p
e
o
f
S
tu
d
y
N
u
m
b
er
o
f
p
ar
ti
ci
p
an
ts
P
at
ie
n
ts
w
h
o
re
ce
iv
ed
th
al
id
o
m
id
e
D
ai
ly
d
o
se
o
f
T
h
al
id
o
m
id
e
D
u
ra
ti
o
n
o
f
th
er
ap
y
C
o
-i
n
te
rv
en
ti
o
n
s
S
id
e
ef
fe
ct
s
at
tr
ib
u
ta
b
le
to
th
al
id
o
m
id
e
N
ab
ar
ro
et
a
l.
2
0
1
6
(1
5
)
R
et
ro
sp
ec
ti
v
e
st
u
d
y
N
¼
3
0
N
¼
2
7
1
7
M
;
1
0
F
1
2
·5
–
5
0
0
m
g
M
ed
ia
n
o
f
1
6
m
o
n
th
s
P
re
d
n
is
o
lo
n
e
C
lo
fa
zi
m
in
e
A
za
th
io
p
ri
n
e
T
ir
ed
n
es
s
(6
1
%
),
C
o
n
st
ip
at
io
n
(1
5
%
),
D
iz
zi
n
es
s
(1
5
%
)
R
iv
et
t
A
.L
.J
.
(U
n
p
u
b
li
sh
ed
)
2
0
1
0
(4
0
)
R
et
ro
sp
ec
ti
v
e
S
tu
d
y
N
¼
1
0
2
N
¼
1
0
1
1
0
0
–
3
0
0
m
g
ta
p
er
ed
d
o
w
n
to
o
n
ce
ev
er
y
1
0
o
r
1
5
d
ay
s
in
so
m
e
ca
se
s
M
ea
n
1
4
·9
m
o
n
th
s
P
re
d
n
is
o
lo
n
e
M
D
T
C
lo
fa
zi
m
in
e
C
o
n
st
ip
at
io
n
(5
0
%
),
D
iz
zi
n
es
s
(1
0
%
),
S
ed
at
io
n
(6
%
),
P
er
ip
h
er
al
n
eu
ro
p
at
h
y
(1
ca
se
)
D
e
L
as
A
g
u
as
1
9
7
1
(3
8
)
R
et
ro
sp
ec
ti
v
e
st
u
d
y
N
¼
1
5
9
N
¼
1
5
9
In
cl
u
d
in
g
2
6
F
1
0
0
–
5
0
0
m
g
4
5
–
8
5
d
ay
s
A
v
er
ag
e
o
f
1
m
o
n
th
C
o
rt
ic
o
st
er
o
id
s
S
le
ep
in
es
s
(1
5
%
),
C
o
n
st
ip
at
io
n
(3
%
),
A
b
d
o
m
in
al
ty
m
p
an
is
m
(2
w
o
m
en
)
M. Mahmoud and S.L. Walker154
administered throughout the trial period.45 80% of the subjects included in Darlong’s study
were already corticosteroid-dependent. Even though the adverse effects of the prolonged use
of corticosteroids were seen to decline during treatment with thalidomide, 8 patients were
reported to have died from its sequelae.41
In the retrospective study by Feuth NFI deteriorated in 25% of 36 ENL patients who
received thalidomide and 14% of individuals who received corticosteroids. The authors found
no significant difference but did suggest the possibility of thalidomide contributing to the
deterioration.42
Other complaints included increased drowsiness, asthenia and somnolence. One study
documented incidence(s) of peripheral oedema which was controlled by reduction of
thalidomide dosage.45 Constipation was documented in two of these studies whilst other
studies had reports of nausea, mucosal dryness, and loss of appetite.
Case reports
The age range of individual cases was 19–70 years with only three reports of female patients
aged 33, 37 and 61 years.46 – 48 Two women of childbearing age were treated with
thalidomide. The contraceptive means employed in these cases was unclear, but no report of
pregnancy was recorded.46 – 48 The maximum dose of thalidomide recorded was 400 mg.49,50
All but two cases reported co-intervention with corticosteroids, one of which oral
corticosteroids were discontinued before initiation of thalidomide.51 Thalidomide was
withdrawn as a consequence of its adverse effects in 12 cases.48 – 50,52 – 60
Vaso-occlusive disease was the most frequent ADR described in the case reports. All 12
reports of DVT occurred during joint therapy with corticosteroids, further strengthening the
evidence of increased risk of DVT during combined thalidomide and corticosteroid therapy.6
In one case DVT occurred as early as 6 days into therapy.61 Sharma’s case with adherent
venous thrombosis had been on thalidomide for 3 weeks but developed DVT 5 days after co-
intervention with pulsed dexamethasone-cyclophosphamide.48 Cases were adequately
managed using thromobolytics and a vena cava implant was administered in one case.56 In
four cases of thromboembolism, thalidomide therapy was restarted without any further issues
following introduction of anticoagulants.46,56,61
Peripheral neuropathy was the second most common ADR reported in three patients, all
of which resolved on withdrawal of the drug.52,55,62 Neuropathy manifested in the form of
new glove-and-stocking distribution sensory neuropathy or worsening of ENL induced
neuropathy. One case of neuropathy was undoubtedly associated with thalidomide use by
confirmation from nerve conduction studies.62
In addition to the ADRs reported in larger studies a patient with ENL who developed
chromoblastomycosis and mucormycosis during corticosteroid and thalidomide therapy was
reported.63 Sudden unexplained death of a 70-year-old male patient on MDT and thalidomide
was reported.51
Discussion
Thalidomide was introduced for use as a sedative; therefore, somnolence is expected to be
commonly associated with use of the drug. It is therefore unpleasant for patients to perform daily
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work-related as well as social activities whilst on thalidomide. This therefore limits its use in
outpatients especially in severe ENL where high doses at increased frequencies will be required.
Management of cutaneous manifestations may be challenging due to the large spectrum
of lesions manifested. Symptoms should therefore be monitored for and individualised for
each patient.
Constipation is also frequently encountered and could have been missed or omitted in
case reports in favour of more severe adverse events. Constipation can prove uncomfortable
for patients. Patients should preferably be informed of the likelihood of this and managed
appropriately if it occurs.
Peripheral neuropathy has been associated with thalidomide owing to demyelinatory and
inflammatory changes observed via nerve conduction studies of patients on thalidomide.16,64
In this review however, neuropathy recorded could not always be confidently associated with
thalidomide. Differentiating between NFI of thalidomide and that caused by ENL is difficult.
The most commonly recorded ADR in the case reports was vasculo-occlusive disease.
Thrombo-embolism was reported in one-third of the documented thrombosis cases.52,53,65,66
Thrombosis in thalidomide therapy in other diseases is common especially when co-
administered with glucocorticoids.67 A project undertaken by the research on adverse drug
events and reports (RADAR) documented the occurrence of 695 cases of venous
thromboembolism among cancer patients treated with thalidomide, chemotherapy, and/or
dexamethasone over a period of 8 years.68 DVT has been reported in 30% of patients treated
for myeloma in doses as low as 100 mg and without corticosteroid use,20 in this review
however, thromboembolic events ranked low on the list of ADRs associated with thalidomide
therapy. Aspirin was used as a prophylaxis for thrombosis in a retrospective study involving
73 participants for a period of one year.41
Limitations of the study
Most trials either failed to include women of childbearing age or non-randomly assigned
women to groups excluded from thalidomide.
Another drawback encountered is the quality of the papers reviewed (Appendix 2). Some
of the best described and most recent studies were small and/or had a short duration of follow
up. Studies without quantifiable ADRs were difficult to include in the review due to the
constraints they pose for analysis. There was immense variability in data collection methods
employed by the researchers making data extraction challenging.
ADR of thalidomide was not the primary point of any of the studies and were not always
clearly defined. Concomitant administration of other drugs such as MDT and corticosteroids
may influence the outcome of the treatment. ADRs reported could be due to other drugs
administered or even due to the ENL reaction itself. As such, the ADRs reported in these
studies cannot be entirely attributable to thalidomide.
Recommendations
IMPLICATIONS FOR PRACTICE
Thalidomide is a potentially safe and effective drug for use in the management of ENL
episodes. Thalidomide can be used to decrease the adverse effects of long-term
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corticosteroids and as an alternative to its use. Thromboembolism is a potentially fatal event
and the role of prophylaxis in patients on both steroids and thalidomide requires further
research.
Patients should be monitored closely for thalidomide related adverse effects. A
programme similar to the STEPS programme should be followed for all patients on
thalidomide. The possibility of subsidies from leprosy programmes should be considered in
order to reduce the costs of thalidomide therapy borne by the patients.
IMPLICATIONS FOR RESEARCH
Large, prospective longitudinal studies of thalidomide use in ENL need to address the ADR
profile of thalidomide in patients with ENL. Patient perceptions of the drug and its tolerability
would be an important component of this.
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1. APPENDICES
1.1. Appendix 1: Search strategy
#1. Leprosy OR lepromatous OR lepra* OR “Hansen* disease”
#2. “Leprosy reaction” OR “lepr* reaction” OR “borderline leprosy” OR “type 2 reaction”
OR “ENL” OR “erythema nodosum leprosum” OR “erythema nodosum” “lepromatous
leprosy”
#3. Thalidomide OR thalidomide* OR immunoprin OR “a- (N-phthalimido) glutarimide
#4. “Adverse effects” OR “side effects” OR “harmful effects” OR “adverse events” OR “AE”
OR “drug reaction” OR reaction OR “complications of” OR “adverse drug reaction”
#5. (#1 AND #2 AND #3 AND #4)
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1.2. Appendix 2: Critical appraisal tables
RCTs
Appropriate
randomization?
Concealment
allocation?
Outcome data
complete?
Dropout
rate low?
Iyer et al. 1971 Yes Yes Yes Yes
Kaur et al. 2009 Yes Unclear Yes Yes
Pearson & Vedagiri 1969 Yes Yes Yes Yes
Ramanujam et al. 1975 Yes No Yes No
Sheskin & Convit 1969 No Yes Yes Unclear
Sheskin 1965 Unclear Yes Yes Yes
Villahermosa et al. 2005 Yes Yes Yes Yes
Waters 1971 Unclear Yes Yes Yes
Non-RCTs
Bias
minimized?
Measurement
appropriate?
Groups similar
(or differences
analysed)?
High response
rate/appropriate
follow-up
Chandorkar et al. 1984 No Yes Unclear Yes
Convit et al. 1967 Unclear Yes Yes Yes
Jadhav et al. 1990 No Yes Unclear Yes
Parikh et al. 1986 No No No Yes
Ramu & Girdhar 1979 No Yes Yes Yes
Descriptive studies
Sampling
appropriate?
Sample representative
of population?
Measurement
appropriate?
Complete data/high
response rate?
Ahamed Riyaz et al. 2011 Unclear Yes Yes Yes
Rivett A.L.J. 2010 Yes Yes Yes Yes
Basilio et al. 2012 Unclear Unclear Yes Yes
Brito et al. 2010 Unclear Yes Yes Unclear
Budania & Kar 2014 Yes Yes Yes No
Burdick & Ramirez 2005 Yes Yes Yes Yes
Chaudhry et al. 2009 Unclear Yes Yes Yes
Chhabria et al. 2017 Yes Yes Yes Yes
Darlong et al. 2016 Yes Yes Unclear Yes
De Las Aguas 1971 Yes Yes Unclear Yes
Dipak et al. 2012 Unclear Yes No No
Ferrari et al. 2002 Unclear Yes No Yes
Feuth et al. 2008 Unclear Yes No No
Forno et al. 2010 Unclear Yes No No
Kar & Gupta 2016 No Yes Yes Yes
La Rosa & Casciano 1968 Unclear Yes Unclear No
Leon et al. 2015 Unclear Yes Unclear No
Magora et al. 1970 Unclear Yes Yes Yes
Medeiros et al. 2009 Unclear Yes Yes Yes
Mehta 2008 Unclear Yes Yes No
Nabarro et al. 2016 Yes Yes Yes Yes
Petiti-Martin Hebe et al. 2013 Unclear Yes Yes Yes
Ramien et al. 2011 Unclear Yes Yes Yes
Salafia & Kharkar 1988 Unclear Yes No No
Sharma et al. 2004 Yes Yes No Yes
Sharma et al. 2005 Yes Yes Yes Yes
Valente & Vieira 2010 Yes Yes Yes Yes
Vetrichevvel et al. 2008 Yes Yes Yes Yes
Yamaguchi et al. 2012 Yes Yes Yes Unclear
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